Nacimbio enhances the product-portfolio of immunobiological and ARV drugs
National Immunobiological Company operating as part of Rostec State Corporation has established a joint venture with Ishvan Pharmaceutical Ltd (U.A.E.). Pharm Aid Ltd. will produce combined and immunobiological medicinal products in Russia.
Nacimbio and Ishvan own 49 % and 51 % of Pharm Aid Ltd, respectively. Kirill Mizerov has been appointed CEO of the new company. The company will transfer production technologies for new combined drugs and active pharmaceutical ingredients for the treatment of hepatitis C, HIV and TB. Along with it, there will be transfer of technologies for the production of vaccines, biologicals and biosimilars.
“We are pleased to announce the beginning of Nacimbio and Ishvan Pharmaceutical Ltd collaboration. We are currently busy negotiating with potential partners for technology transfer and expect Pharm Aid Ltd to show the first tangible results in September of 2017,” said Kirill Mizerov.
“Russian pharmaceutical market develops dynamically. We have been looking for a reliable Russian partner for a long time, and, in our opinion, cooperation with Nacimbio opens new and interesting perspectives for us. The company has a professional team with a high scientific potential, is well known in the industry. We appreciate their aspirations for innovation through technology localization and transfer. As a result of establishing the joint venture with Nacimbio new drugs manufactured in Russia will be released to the market, where they were not available previously,” commented Mr. Sanjeev Nanda, Managing Director of Ishvan Pharmaceutical Ltd.
Earlier the company signed an agreement with R-Pharm, to establish a joint venture for manufacturing antiretroviral medicines, with Binnopharm on joint production of a multicomponent vaccine. The parties will have concluded binding agreements on both the projects by the end of the third quarter of 2017.